0001462573-18-000002.txt : 20180621 0001462573-18-000002.hdr.sgml : 20180621 20180621122137 ACCESSION NUMBER: 0001462573-18-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180621 DATE AS OF CHANGE: 20180621 EFFECTIVENESS DATE: 20180621 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AgeX Therapeutics, Inc. CENTRAL INDEX KEY: 0001708599 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821436829 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-315096 FILM NUMBER: 18911467 BUSINESS ADDRESS: STREET 1: 1010 ATLANTIC AVENUE STREET 2: SUITE 102 CITY: ALAMEDA STATE: CA ZIP: 94501 BUSINESS PHONE: 510-521-3390 MAIL ADDRESS: STREET 1: 1010 ATLANTIC AVENUE STREET 2: SUITE 102 CITY: ALAMEDA STATE: CA ZIP: 94501 D 1 primary_doc.xml X0708 D LIVE 0001708599 AgeX Therapeutics, Inc. 1010 ATLANTIC AVENUE SUITE 102 ALAMEDA CA CALIFORNIA 94501 510-521-3390 DELAWARE None None Corporation true 2017 Michael D. West 1010 Atlantic Avenue Suite 102 Alameda CA CALIFORNIA 94501 Executive Officer Director President and CEO Russell Skibsted 1010 Atlantic Avenue Suite 102 Alameda CA CALIFORNIA 94501 Executive Officer Chief Financial Officer Alfred D. Kingsley 150 E. 57th Street Suite 24E New York NY NEW YORK 10022 Executive Officer Director Executive Chairman Michael H. Mulroy 1010 Atlantic Avenue Suite 102 Alameda CA CALIFORNIA 94501 Director Not Applicable BioTime, Inc. 1010 Atlantic Avenue Suite 102 Alameda CA CALIFORNIA 94501 Promoter Parent company of Issuer John Mauldin 1010 Atlantic Avenue Suite 102 Alameda CA CALIFORNIA 94501 Director Biotechnology Decline to Disclose 06b false 2018-06-06 false true false 50000 5000000 5000000 0 false 1 0 0 2300000 true Amount includes payments to parent company for use of office and laboratory facilities and administrative and finance personnel, and salaries of executive officers and directors fees. false AgeX Therapeutics, Inc. /s/ Russell Skibsted Russell Skibsted Chief Financial Officer 2018-06-20